Table 3 Treatment subgroups

From: From trial data to personalized medicine: a validated framework with an application to Crohn’s disease

Drug Class Preference

Subgroup

N (%)

Anti-TNF

TNF > (IL = INT)

2021 (35)

TNF > INT > IL

43 (0.8)

Anti-TNF, Anti-Interleukin-12/23

(IL = TNF) > INT

354 (6)

Anti-Interleukin-12/23

IL > (TNF = INT)

138 (2.5)

IL > TNF > INT

1 (0.02)

Other

(TNF = INT) > IL

4 (0.07)

No Preference

(TNF = IL = INT)

3142 (55)

  1. The finalized mixed effects models were used to simulate counterfactual outcomes under all possible treatment scenarios. The modeled outcomes and the associated uncertainties in these outcomes were used to perform pairwise t-testing to assess evidence for rank-ordered preferences across drug classes. Distinct patterns of rank-orderings were used to establish membership in one of 6 subgroups. Subjects without sufficient statistical evidence (alpha = 0.05) of a more efficacious response to any one drug class were placed into a 7th category (no preference). TNF = anti-tumor necrosis factor, IL = anti-interleukin-12/23, INT = anti-integrin.
Back to article page